Summary This is a study of immune responses generated by mutant ras peptide vaccination of patients with pancreatic adenocarcinoma. Responding T cells from one patient were cloned and two CD4+ T-lymphocyte clones (TLC) specific for the 12 Val peptide and restricted by HLA-DR6 or DQ2 were obtained. These class II molecules have not previously been found to bind or present mutant ras peptides to T cells. The DR6-restricted TLC showed marked cytotoxicity against autologous target cells pulsed with the 12Val peptide. Target cells pulsed with the control peptide were not killed. Responding T cells from another patient showed crossreactivity towards the homologous ras peptides. Investigation by limiting dilution analysis (LDA) revealed different T-cell precursor frequencies for the immunising, mutant ras peptide (1:28 000), compared with the normal ras peptide (1: 1 10 000).
Somatic point mutations of K-ras oncogenes occur in approximately 90% of pancreatic adenocarcinomas (Almoguera et al., 1988) . Activating point mutations of K-ras oncogenes predominantly occur at codons 12, 13 or 61 and result in corresponding single amino acid substitutions within the p21 protein. In pancreatic adenocarcinomas, the mutations most commonly occur at codon 12 of K-ras, and the spectrum of different amino acid substitutions is limited (Capella et al., 1991) . The mutations disrupt the normal signalling function of p21 ras and contribute to malignant transformation (Seeburg et al., 1984; Der et al., 1985) . Mutant p21 ras are not expressed by normal tissue and thus represent true tumour-specific antigens. Mutant ras proteins or corresponding peptide sequences have previously been shown to be immunogenic both in healthy individuals (Jung and Schluesener, 1991) and in cancer patients (Gedde-Dahl et al., 1992a; Fossum et al., 1994) . Most responding T cells have been of the CD4+ phenotype, and their peptide specificity has been described in detail . Ras peptide binding to HLA class II molecules seems to be promiscuous Johansen et al., 1994) and involves class II molecules of all isotypes . Also, human CD8 + TLCs specific for a single ras mutation and capable of killing tumour cells harbouring the same mutation have been described (Fossum et al., 1995) . Together these results suggest that ras peptide vaccination of cancer patients with a verified ras mutation, might be applied as a therapeutic principle of specific immunotherapy.
In a pilot clinical study, we have vaccinated pancreatic carcinoma patients with synthetic ras peptide-pulsed autologous antigen-presenting cells (APCs), and thereby induced peptide specific T-cell responsiveness in vivo (Gjertsen et al., 1995 (Gjertsen et al., , 1996 . To characterise the specificity further, HLA restriction and functional properties of these in vivo activated T cells, TLCs were generated from one of the vaccinated patients. We report here that the vaccination procedure resulted in a sufficient clonal expansion of CD4+ T cells specific for the Glyl2-+Val mutation to allow detection in peripheral blood and subsequent cloning. The HLA class II molecules involved in binding and presenting of these synthetic ras peptides to T cells in vivo were indentified in antibody-blocking experiments and by using a panel of HLAhomozygous B-lymphoblastoid cell lines (B-LCLs) as APC.
We also provide evidence that one of the CD4+ TLCs has cytotoxic properties and is capable of specifically killing autologous target cells pulsed with the appropriate ras peptide. Different T-cell precursor frequencies against mutant and normal ras peptides in peripheral blood were determined by LDA.
Materials and methods

T-cell donors
The male patient (donor 1), 49 years old at diagnosis, had a moderately differentiated, unresectable adenocarcinoma of the pancreatic head. The HLA type of donor 1 was HLA-A1,2; B8,35; DR3,6 (DRB1*0301,1401); DQ1,2 (DQA 1*0101,0501;DQB1 *0201,0501,3). The K-ras mutation Glyl2--Val was identified in DNA from formalin-fixed paraffin-embedded tumour tissue using a highly sensitive technique (Kahn et al., 1991) . The female patient (donor 2), 39 years old at diagnosis, had a poorly differentiated, unresectable adenocarcinoma of the pancreatic head with one liver metastasis. The HLA type of donor 2 was HLA- A3, 19; B7, 12; DR4, 7; DQ2, 3 . The K-ras mutation in tumour tissue from donor 2 was found to be Glyl2-.Asp. Both patients were vaccinated with autologous ras peptide-pulsed APC [freshly isolated, unfractionated peripheral blood mononuclear cells (PBMCs)], and two and three rounds of vaccination induced proliferative T-cell responses in PBMCs of donor 1 and donor 2 respectively (Gjertsen et al., 1995) .
Cells and media
PBMCs were prepared by centrifugation over Lymphoprep (Nycomed, Oslo, Norway) . B-LCLs used as APC were from the 10th and 11th International Histocompatibility Workshop cell panels. The HLA profiles of the different cell lines used are given in Table I required for lysis (data not shown). We were, however, unsuccessful in establishing a tumour cell line from the ascites fluid of the patient, and could, therefore, not evaluate a possible cytotoxic effect on the autologous tumour cells.
Determination of different T-cell precursor frequencies against mutant and normal ras peptides in peripheral blood In donor 2, a proliferative T-cell response against mutant rasderived peptides was induced after three rounds of peptide vaccination. The time span from onset of treatment until detection of responding T cells in peripheral blood was, however, approximately 40 days in both patients (Gjertsen et al., 1996) . The responding T cells from donor 2 were characterised by cross-reactivity to all the homologous ras peptides tested encompassing position 12, including the nonmutated ras peptide (Figure 4) . We made several attempts to clone these cross-reactive T cells, but were not successful. To sort out whether these cross-reacting T cells in PBMCs were made up of one set of T cells that cross-reacted with the homologous peptides or actually consisted of two or more sets of T cells that reacted specifically to the different peptides, a LDA was set up to investigate different T-helper cell precursor frequencies. We found a T-cell precursor frequency of 1: 28 000 PBMCs for the immunising 12Asp peptide compared with a T-cell precursor frequency of 1:110 000 PBMCs for the 12Gly peptide expressing normal ras ( Figure 5 ). These results suggest that ras peptide immunisation of this donor may have produced a clonal expansion of at least two different sets of T cells, since the Tcell precursor frequencies are not identical.
Discussion
Cancer vaccines based on defined peptide epitopes are now being tested in a number of clinical trials. In these approaches it is of great importance to characterise the in vivo activated T cells of the responding patients after peptide vaccination. Here, we report that the induction of 12Val peptideresponsive T cells in the pancreatic carcinoma patient after mutant ras peptide vaccination resulted in a sufficient expansion of CD4+ T cells specific for the 12Val peptide to allow cloning of these T cells in vitro. Our vaccination strategy is based on earlier observation that ras peptide None of the five patients demonstrated a T-cell response towards the K-ras mutation found in their tumour before vaccination (Gjertsen et al., 1995) . This could theoretically result from tolerance induction, leading to inactivation of T cells with the appropriate receptor. However, our results demonstrate that the lack of T-cell responsiveness observed initially in these patients was not due to absence of specific T cells in the repertoire or lack of HLA-molecules with (Tsang et al., 1994) . Future studies with HLA-matched tumour cell lines will hopefully allow a more detailed knowledge of the functional properties of these in vivo activated, cytotoxic T 
cells.
The difference between the mutant ras peptides and the peptide representing normal p21 ras is only one amino acid in position 12, and can give rise to T cells that may show varying degrees of cross-reactivity (Gedde-Dahl et al., 1992b) . This presents the possibility that some T cells may be autoreactive and, therefore, potentially harmful. In our pilot clinical study (Gjertsen et al., 1996) this did not seem to be the case, since no side-effects or possible autoreactivity were observed in the patient having cross-reactive T cells. In a mouse model system, where CD8 + T cells specific for different ras epitopes were induced following immunisation with a ras-vaccinia virus construct, only T cells specific for mutant ras were able to lyse target cells harbouring a ras mutation (Skipper et al., 1993) , indicating that endogenous expression of p21 ras by normal cells may only result in subthreshold amounts of ras peptide and is therefore insufficient for T-cell recognition. In this context, it is of importance that in many cases of human malignancies, the ras oncogene family seems to be overexpressed compared with normal tissues (Slamon et al., 1984; Spandidos and Kerr, 1984) . The basis for the cross-reactivity against the common mutations in position 12, as well as against the peptide expressing normal ras observed in donor 2, seemed to be a result of in vivo activation of a set of T cells, which was cross-reactive. The precursor frequency of these cells (1:110 000) was lower than the precursor frequency of T cells recognising the Asp12 mutation. This precursor frequency may be too low to cause any side-effects in the form of autoimmunity.
In conclusion, we have shown that ras peptide vaccination of patients with pancreatic adenocarcinoma can result in the induction of T 
